Abstract 2749
Background
With the expanding use of CPI in different types of cancer, we have been challenged with the lack of safety and efficacy data of CPI post allogeneic stem cell therapy (SCT).
Methods
We systematically reviewed our institutional databases through March 2018 and identified patients (pts) who received CPI for treatment of cancer after allogeneic SCT. In addition, we systematically reviewed the literature through August 2018 to identify studies reporting use of CPIs post-allogeneic SCT. We evaluated the prevalence of graft vs host disease (GVHD), immune-related adverse events (irAEs), tumor response, and mortality after CPI.
Results
A total of 38 pts were identified (10 from institutional databases & 28 from literature). The median age was 37.5 years (range 10–68 yrs). The most commonly used CPI was anti-PD1 84 %. Cancer types included hematologic malignancies (n = 36); primarily Hodgkin lymphoma in 58%, and solid tumors (n = 2). Median time to CPI initiation post SCT was 1.6 years (range 0.92–32 yrs). More than half of pts (59 %) were maintained on immunosuppressive agents: brentuximab vedotin, cyclophosphamide, and low dose prednisone at CPI initiation. GVHD occurred in 34.2 % (n = 13); nine were specified having acute GVHD (82%). The median time from initiation of CPI to GVHD was 14 days (range 5-21 days). In most pts, GVH was treated with steroids. Two thirds of pts achieved complete or partial tumor remission (ORR 66%), while 28% had disease progression. In pts who developed GVHD the ORR was 91.2%. Interestingly, of the 25 pts who were reported to have no GVHD, 10 had irAEs. There were total of 34% of death (n = 13), including 5% only (n = 2) were attributed to GVHD, while the remaining were secondary to either progression of disease, CPI irAE’s (Pneumonitis, Myocarditis), and other causes.
Conclusions
The use of CPI post-SCT has a significant anti-tumor response, but it was associated with an increased risk of acute GVHD. Prospective studies in this population (CPI post-SCT) with longitudinal on treatment biopsies are needed to understand the differences between allo-immunity, tumor immunity and auto-immunity (irAE).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Adi Diab.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3988 - Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial.
Presenter: Sara Santagata
Session: Poster Display session 3
Resources:
Abstract
2142 - Low NK Cell Abundance Correlates with High Expression of PD-1 in CD8+ T Cells
Presenter: Moon Hee Lee
Session: Poster Display session 3
Resources:
Abstract
5501 - Tobacco smoking is associated with the immune suppressive microenvironment in head and neck squamous cell carcinoma (HNSCC)
Presenter: Christine Chung
Session: Poster Display session 3
Resources:
Abstract
5726 - Evaluation of Antibody-Dependent Cell Cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy.
Presenter: Francesca Sparano
Session: Poster Display session 3
Resources:
Abstract
2534 - Radiomic Signatures for Identification of Tumors Sensitive to Nivolumab or Docetaxel in Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Presenter: Laurent Dercle
Session: Poster Display session 3
Resources:
Abstract
3366 - Analysis of gut microbiota in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoints blockers
Presenter: FEIYU ZHANG
Session: Poster Display session 3
Resources:
Abstract
2089 - Pathogenesis of Myocarditis Following Treatment with Immune Checkpoint Inhibitors in a Cynomolgus Monkey Model
Presenter: Changhua Ji
Session: Poster Display session 3
Resources:
Abstract
4463 - Effects of dietary restriction in cancer patients receiving irinotecan
Presenter: Ruben Van Eerden
Session: Poster Display session 3
Resources:
Abstract
4841 - Investigating the Link between Burn Injury and Tumorigenesis
Presenter: Lucy Barrett
Session: Poster Display session 3
Resources:
Abstract
4619 - Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in male breast cancer patients
Presenter: Joanna Huszno
Session: Poster Display session 3
Resources:
Abstract